-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O14BwIEKlERpb8iywp4d6lndjbUHENfjhOe/ITbno6uYCb3YcP9BqJaItc7tx5UN GL14UWvBj4U0GPfIbUZyFw== 0001209191-05-060886.txt : 20051202 0001209191-05-060886.hdr.sgml : 20051202 20051202164604 ACCESSION NUMBER: 0001209191-05-060886 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051201 FILED AS OF DATE: 20051202 DATE AS OF CHANGE: 20051202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1204 BUSINESS ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUYER DAVID R CENTRAL INDEX KEY: 0001277476 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 051241366 BUSINESS ADDRESS: STREET 1: EYETECH PHARMACEUTICALS INC STREET 2: 500 SEVENTH AVE. CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 212 824 3100 MAIL ADDRESS: STREET 1: 3 TIMES SQUARE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 4 1 doc4.xml FORM 4 SUBMISSION X0202 4 2005-12-01 0 0000729922 OSI PHARMACEUTICALS INC OSIP 0001277476 GUYER DAVID R C/O OSI PHARMACEUTICALS, INC. 58 SOUTH SERVICE RD., SUITE 110 MELVILLE NY 11747 0 1 0 0 Exec. VP & CEO (OSI) Eyetech Stock Option (Right to Buy) 23.83 2005-12-01 4 A 0 100000 0.00 A 2006-12-01 2012-11-30 Common Stock 100000 100000 D Twenty-five percent of the option will become exercisable one year after date of grant and the remainder will vest ratably on a monthly basis over the succeeding 36 months. The stock option was granted pursuant to one of the Issuer's incentive and non-qualified stock option plans and is exempt under Rule 16b-3. Includes only options with the same termination date. Michael G. Atieh by Power of Attorney 2005-12-02 -----END PRIVACY-ENHANCED MESSAGE-----